Abnormal CD56 expression in hematologic cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

CD56 (NCAM) is normally found on natural killer cells and some T cells but has been reported in multiple myeloma and linked to worse outcomes in AML. This observational study will measure CD56 expression patterns in newly diagnosed patients with a range of hematologic malignancies using clinical samples collected at Assiut University. The investigators aim to map which disease types and cell populations show ectopic CD56 and to relate expression patterns to clinical categories. Findings will be descriptive and hypothesis-generating rather than interventional.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with hematologic malignancies.
* Newly diagnosed

Exclusion Criteria:

* Patients with hematologic disorders other than hematologic malignancies.

Where it's running

• Assiut university
  Asyut, Egypt Recruiting
• Assiut University
  Asyut, Egypt Completed

Study contacts

• Study coordinator: asmaa H mohamed, R.DR
• Email: a94asmaa@gmail.com
• Phone: +201024850070

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tempus Open Link registry for cancer patients using Olivia platform

  This registry tests whether Olivia can securely enroll cancer patients and combine their health data from EHRs and patient-reported outcomes to build a large, de-identified dataset.

  Recruiting Tempus AI · Chicago, Illinois · NCT07756034

• Genetics of Blood Cancers in the U.S. population

  This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.

  Recruiting Rutgers, The State University of New Jersey · Piscataway, New Jersey · NCT07714044

• Leflunomide to prevent CMV reactivation after haploidentical stem cell transplant

  This study tests whether leflunomide can prevent CMV reactivation in adults undergoing haploidentical hematopoietic stem cell transplantation.

  Recruiting Phase 2 Tata Memorial Centre · Navi Mumbai, Maharashtra and 2 other locations · NCT07709013

• MK-1045-006: testing a new treatment for B-cell cancers like CLL and SLL

  This trial will test MK-1045 in people with relapsed or treatment‑refractory CLL/SLL to see if it’s safe and how well it works.

  Recruiting at 8 sites Phase 2 Merck Sharp & Dohme LLC · Medellín, Antioquia and 7 other locations · NCT07709000

• Predicting bleeding risk in patients with severe thrombocytopenia using a viscoelastic and clinical score

  We test a new score that combines viscoelastic test results with clinical data to see if we can predict bleeding risk in adults with malignant hematologic disorders and very low platelets.

  Recruiting Centre Hospitalier Annecy Genevois · Épagny, Auvergne-Rhône-Alpes · NCT07653672

• Ruxolitinib to prevent graft-versus-host disease after allogeneic stem cell transplant

  This trial will test whether adding ruxolitinib to standard drugs better prevents chronic graft-versus-host disease in adults receiving an allogeneic stem cell transplant for blood cancers.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07359859

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.